J-mab Therapeutics,Inc.

Close MENU

'Giant pore formation on the surface of cancer cells' We established new type of therapeutic mAbs against malignant lymphomas. Treatment with Anapocosis mAb induced the formation of large pores on the surface of target lymphoma cells within 30 min. The pore diameter is 100 times larger than complements or perforin-formed pores.

'Giant pore formation on the surface of cancer cells' We established new type of therapeutic mAbs against malignant lymphomas. Treatment with Anapocosis mAb induced the formation of large pores on the surface of target lymphoma cells within 30 min. The pore diameter is 100 times larger than complements or perforin-formed pores.

NEWS

September 15, 2025NEW: Announcement Exhibition at JHVS (JAPAN HEALTHCARE VENTURE SUMMIT) (V-85)
We are pleased to announce that we will be exhibiting at JHVS.
Date and Time: October 8-10, 2025, 10:00 AM - 5:00 PM
Location: Pacifico Yokohama
Booth Number: V-85
March 20, 2024: Video showing humanized 4713 (h4713) monoclonal antibody (mAb) killing malignant lymphoma cells in less than an hour.
March 1, 2021: J-mab was published in Nikkei Biotech.
March 1, 2021: J-mab's English site is renewed !